Managing patients with type 2 diabetes— a cardiometabolic pathway for a cardiovascular risk reduction approach

Leeds supplement_digital_index image

This supplement has been commissioned and funded by the Boehringer Ingelheim and Lilly Diabetes Alliance and developed in partnership with Guidelines in Practice. Please see bottom of page for full disclaimer. 

View Jardiance®(empagliflozin) prescribing and adverse event reporting information

Content for healthcare professionals

Access to this content is restricted to UK-based doctors, nurses, and pharmacists

If you are a UK-based doctor, nurse, or pharmacist, you must sign in to your account or register (for free) if you do not already have one. 

Return to homepage